98%
921
2 minutes
20
Background: The recent pandemic has made it more challenging to assess patients with suspected obstructive sleep apnea (OSA) with in laboratory polysomnography (PSG) due to concerns of patient and staff safety. The purpose of this study was to assess how Level II sleep studies (LII, full PSG in the home) might be utilized in diagnostic algorithms of suspected OSA using a theoretical decision model.
Methods: We examined four diagnostic algorithms for suspected OSA: an initial PSG approach, an initial LII approach, an initial Level III approach (LIII, limited channel home sleep study) followed by PSG if needed, and an initial LIII approach followed by LII if needed. Costs per patient assessed was calculated as a function of pretest OSA probability and a variety of other variables (e.g. costs of tests, failure rate of LIII/LII, sensitivity/specificity of LIII). The situation in British Columbia was used as a case study.
Results: The variation in cost per test was calculated for each algorithm as a function of the above variables. For British Columbia, initial LII was the least costly across a broad range of pretest OSA probabilities (< 0.80) while initial LIII followed by LII as needed was least costly at very high pretest probability (> 0.8). In patients with a pretest OSA probability of 0.5, costs per patient for initial PSG, initial LII, initial LIII followed by PSG, and initial LIII followed by LII were: $588, $417, $607, and $481 respectively.
Conclusions: Using a theoretical decision model, we developed a preliminary cost framework to assess the potential role of LII studies in OSA assessment. Across a broad range of patient pretest probabilities, initial LII studies may provide substantial cost advantages. LII studies might be especially useful during pandemics as they combine the extensive physiologic information characteristic of PSG with the ability to avoid in-laboratory stays. More empiric studies need to be done to test these different algorithms.
Supplementary Information: The online version contains supplementary material available at 10.1186/s41606-021-00063-5.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279805 | PMC |
http://dx.doi.org/10.1186/s41606-021-00063-5 | DOI Listing |
J Hepatocell Carcinoma
June 2025
Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.
Purpose: Outcomes in the treatment of unresectable infiltrative hepatocellular carcinoma (HCC) are poorly understood, and infiltrative HCC is generally underrepresented in clinical trials. The present study explored outcomes associated with the treatment of infiltrative HCC with various systemic therapies.
Patients And Methods: We enrolled all patients with Barcelona Clinic Liver Cancer stage C infiltrative or multinodular HCC who received first-line systemic therapy between January 2015 and December 2021 at a single center.
Am J Obstet Gynecol
May 2025
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. Electronic address:
Background: Recent evidence from the Chronic Hypertension and Pregnancy trial demonstrates that treatment of even mild chronic hypertension during pregnancy reduces the risk of severe adverse maternal, fetal, and neonatal outcomes. Black patients are disproportionately affected by hypertension-related morbidity during pregnancy. Outside of pregnancy, substantial racial and ethnic differences in antihypertensive medication adherence have been reported.
View Article and Find Full Text PDFBone
February 2025
Department of Mechanical Engineering, University of Alberta, Edmonton, AB, Canada; Department of Biomedical Engineering, University of Alberta, Edmonton, AB, Canada; School of Dentistry, University of Alberta, Edmonton, AB, Canada. Electronic address:
J Hazard Mater
December 2024
CAS Key Laboratory of Design and Assembly of Functional Nanostructures, Fujian Key Laboratory of Nanomaterials, Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences, Fuzhou, Fujian 350002, PR China; Fujian Research Center for Rare Earth Engineering Technology, Xiamen
Nutrients
October 2024
Center for Digestive Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung 404327, Taiwan.
: The diverse effects of fructose and glucose on the progression of metabolic dysfunction-associated steatotic liver disease remain uncertain. This study investigated the effects, in animal models, of high-fat diets (HFDs) supplemented with either glucose or fructose. : Six-week-old, male C57BL/6J mice were randomly allocated to four groups: normal diet (ND), HFD, HFD supplemented with fructose (30% /, HFD + Fru), and HFD supplemented with glucose (initially 30%, HFD + Glu).
View Article and Find Full Text PDF